Myla Goldman

Myla Goldman, M.D., is the Chair of the Division of Neuroimmunology-Multiple Sclerosis and Vice Chair for Faculty Development at Virginia Commonwealth University.

​

Goldman’s research focuses on clinical outcome measures of MS and the impact of co-morbidities on the disease. She has led clinical trials for emerging MS therapies and has an interest in collaborating with VCU’s lab-based, basic science researchers to expand opportunities for translational, patient-centered research

​

When Goldman began her own studies as a neurologist, she said, the field of study was on the brink of significant breakthroughs. 

“It was a very exciting time, with all these new treatments emerging,” Goldman said. “There aren’t as many diseases where therapeutic options are available, and that was very appealing to me.” 

And with those innovative new treatments comes what she considers the most rewarding element of being a physician: building relationships with patients, many of whom are diagnosed in their 30s or 40s and thus face decades living with MS.  

​

“I love that my patients are very engaged in their care, so there is a lot of shared decision-making, a lot of collaborative engagement to create a path forward,” she said. “It’s wonderful that patients have more choices now than they’ve ever had in terms of their therapies.” 

That’s also one of the most challenging aspects, though – patients must consider risks associated with long-term options and how best to sequence their treatments. 

​

​

​